Why the study?
Glycemic variability has emerged as a possible independent risk factor for diabetic neuropathy, an under-characterized contributor to a prevalent complication affecting up to half of diabetic patients.
This review highlights glycemic variability as a potential independent risk factor for diabetic neuropathy and discusses evaluation metrics and treatment strategies.
Glycemic variability monitoring may refine neuropathy risk assessment in diabetes; leaves open whether targeting it improves outcomes.
Diabetic neuropathy is one of the most prevalent chronic complications of diabetes, and up to half of diabetic patients will develop diabetic neuropathy during their disease course. Notably, emerging evidence suggests that glycemic variability is associated with the pathogenesis of diabetic complications and has emerged as a possible independent risk factor for diabetic neuropathy. In this review, we describe the commonly used metrics for evaluating glycemic variability in clinical practice and summarize the role and related mechanisms of glycemic variability in diabetic neuropathy, including cardiovascular autonomic neuropathy, diabetic peripheral neuropathy and cognitive impairment. In addition, we also address the potential pharmacological and non-pharmacological treatment methods for diabetic neuropathy, aiming to provide ideas for the treatment of diabetic neuropathy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: